Methods for treatment with bucindolol based on genetic targeting
AssigneeThe Regents of the University of Colorado, a body corporate
InventorsStephen B. Liggett, Michael Bristow
Life of this patent
Estimating the term…
Abstract
The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the β1-adrenergic receptor (AR).
Claims16
A method for treating a human patient for heart failure, cardiac arrhythmia, or hypertension with bucindolol comprising:
- a) obtaining results from a test that determines whether the patient's genotype is i) homozygous for Arg389 in the β1 adrenergic receptor (AR) gene and ii) homozygous wildtype for Del322-325 in the α2c AR gene;
- and,
- b) then treating the patient with bucindolol if the test indicates that the patient's genotype is homozygous for Arg389 in the β1AR gene or is homozygous wildtype for Del322-325 in the α2c AR gene.
A method for treating a human patient for heart failure, cardiac arrhythmia, or hypertension with bucindolol, comprising administering bucindolol to the patient, wherein the patient has been subjected to a test, said test having identified that the genotype of the patient is (i) homozygous for Arg389 in the β1 adrenergic receptor (AR) gene or (ii) homozygous wildtype for Del322-325 in the α2c AR gene.
A method for treating a human patient for heart failure, cardiac arrhythmia, or hypertension with bucindolol, comprising administering bucindolol to the patient, wherein the patient has been subjected to a test that determines the patient's genotype is (i) homozygous for Arg389 in the β1AR gene and/or (ii) homozygous wildtype for Del322-325 in the α2c AR gene.
Dependencies are inferred from the claim text.